Cargando…
A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy
SIMPLE SUMMARY: Metabolic-associated fatty liver disease (MAFLD) is a chronic liver disease associated with obesity, diabetes mellitus type 2 (DM2), and hyperlipidemia. It can also progress to end-stage hepatocellular carcinoma (HCC); the underlying mechanisms are still unknown, but endogenous (i.e....
Autores principales: | Guo, Feifei, Estévez-Vázquez, Olga, Benedé-Ubieto, Raquel, Maya-Miles, Douglas, Zheng, Kang, Gallego-Durán, Rocío, Rojas, Ángela, Ampuero, Javier, Romero-Gómez, Manuel, Philip, Kaye, Egbuniwe, Isioma U., Chen, Chaobo, Simon, Jorge, Delgado, Teresa C., Martínez-Chantar, María Luz, Sun, Jie, Reissing, Johanna, Bruns, Tony, Lamas-Paz, Arantza, del Moral, Manuel Gómez, Woitok, Marius Maximilian, Vaquero, Javier, Regueiro, José R., Liedtke, Christian, Trautwein, Christian, Bañares, Rafael, Cubero, Francisco Javier, Nevzorova, Yulia A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750626/ https://www.ncbi.nlm.nih.gov/pubmed/35008356 http://dx.doi.org/10.3390/cancers14010192 |
Ejemplares similares
-
Fat: Quality, or Quantity? What Matters Most for the Progression of Metabolic Associated Fatty Liver Disease (MAFLD)
por: Estévez-Vázquez, Olga, et al.
Publicado: (2021) -
An Experimental DUAL Model of Advanced Liver Damage
por: Benedé‐Ubieto, Raquel, et al.
Publicado: (2021) -
Alcohol and Hepatocellular Carcinoma: Adding Fuel to the Flame
por: Ramadori, Pierluigi, et al.
Publicado: (2017) -
Emerging pharmacological treatment options for MAFLD
por: Rojas, Ángela, et al.
Publicado: (2022) -
Guidelines and Considerations for Metabolic Tolerance Tests in Mice
por: Benedé-Ubieto, Raquel, et al.
Publicado: (2020)